NANO DISCOVERY, INC.

nanodiscoveryinc.com

Nano Discovery Inc. is a biotechnology company based in Orlando, Florida, United States. Nano Discovery developed, manufactures and sells single-step and washing-free immunoassay technology, D2Dx™. D2Dx™ is a platform technology that can be used for the detection and analysis of both antibody and antigen proteins. Using the conjugation kits and assay reader from Nano Discovery, any immunoassay can be customized to specific needs within hours. D2Dx™ immunoassay is simple to use with assay results obtained within 5-30 minutes. Nano Discovery’s unique technology and methodology were developed by Dr. Qun (Treen) Huo at the University of Central Florida’s Department of Chemistry and NanoScience Technology Center. Huo used a variety of UCF’s Tech Transfer programs in creating Nano Discovery Inc. at the UCF Business Incubator. The company is led by biotechnology entrepreneur and investor Davian Santana. For more information visit www.nanodiscoveryinc.com and follow us on Twitter @nanodiscovery.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech, AI

FOXO TECHNOLOGIES™ COLLABORATES WITH DATAROBOT TO PAVE THE WAY FOR AI-DRIVEN EPIGENETIC BIOMARKER RESEARCH IN HUMAN LONGEVITY

Businesswire | August 18, 2023

news image

FOXO Technologies Inc. a leader in the field of commercializing epigenetic biomarker technology, has advanced in its mission to utilize the power of epigenetics and artificial intelligence to generate data-driven insights that promote optimal health and longevity. In collaboration with DataRobot, the leader in Value-Driven AI, FOXO has successfully harnessed the powers of predictive AI and high-throughput automation to estimate factors associated with human longevity using epigenetic bioma...

Read More

Industrial Impact

ADM FURTHER EXPANDS MICROBIAL SCIENCE AND TECHNOLOGY INNOVATION CAPABILITIES WITH INVESTMENT IN PRECISION FERMENTATION LEADER ACIES BIO

ADM | October 22, 2021

news image

ADM a global leader in nutrition and agricultural origination and processing, annoThis investment will help ADM more quickly advance projects in the field of precision microbial fermentation by leveraging Acies Bio’s extensive microbial capabilities and contract manufacturing services. “Microbial technology is unlocking disruptive opportunities in sustainable agriculture, sustainable materials and fuels, and alternative proteins, We’re prope...

Read More

Industrial Impact

PHENOMEX'S BEACON® TECHNOLOGY ENABLES EARLY IDENTIFICATION OF POTENT OMICRON-NEUTRALIZING ANTIBODIES

PRNewswire | June 14, 2023

news image

PhenomeX Inc. the functional cell biology company, announced that the Company's technology was recently featured in a groundbreaking study published in Cell Reports titled "Potent Omicron-neutralizing antibodies isolated from a patient vaccinated six months before Omicron emergence" that has revealed the remarkable efficacy of vaccines in generating potent antibodies against emerging variants at an accelerated rate. The study, conducted by researchers from the La J...

Read More

Industrial Impact, Medical

GENPREX STRENGTHENS DIABETES GENE THERAPY PROGRAM WITH LICENSE OF ADDITIONAL TECHNOLOGY FROM UNIVERSITY OF PITTSBURGH

Genprex, Inc. | December 16, 2022

news image

Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene ...

Read More
news image

MedTech, AI

FOXO TECHNOLOGIES™ COLLABORATES WITH DATAROBOT TO PAVE THE WAY FOR AI-DRIVEN EPIGENETIC BIOMARKER RESEARCH IN HUMAN LONGEVITY

Businesswire | August 18, 2023

FOXO Technologies Inc. a leader in the field of commercializing epigenetic biomarker technology, has advanced in its mission to utilize the power of epigenetics and artificial intelligence to generate data-driven insights that promote optimal health and longevity. In collaboration with DataRobot, the leader in Value-Driven AI, FOXO has successfully harnessed the powers of predictive AI and high-throughput automation to estimate factors associated with human longevity using epigenetic bioma...

Read More
news image

Industrial Impact

ADM FURTHER EXPANDS MICROBIAL SCIENCE AND TECHNOLOGY INNOVATION CAPABILITIES WITH INVESTMENT IN PRECISION FERMENTATION LEADER ACIES BIO

ADM | October 22, 2021

ADM a global leader in nutrition and agricultural origination and processing, annoThis investment will help ADM more quickly advance projects in the field of precision microbial fermentation by leveraging Acies Bio’s extensive microbial capabilities and contract manufacturing services. “Microbial technology is unlocking disruptive opportunities in sustainable agriculture, sustainable materials and fuels, and alternative proteins, We’re prope...

Read More
news image

Industrial Impact

PHENOMEX'S BEACON® TECHNOLOGY ENABLES EARLY IDENTIFICATION OF POTENT OMICRON-NEUTRALIZING ANTIBODIES

PRNewswire | June 14, 2023

PhenomeX Inc. the functional cell biology company, announced that the Company's technology was recently featured in a groundbreaking study published in Cell Reports titled "Potent Omicron-neutralizing antibodies isolated from a patient vaccinated six months before Omicron emergence" that has revealed the remarkable efficacy of vaccines in generating potent antibodies against emerging variants at an accelerated rate. The study, conducted by researchers from the La J...

Read More
news image

Industrial Impact, Medical

GENPREX STRENGTHENS DIABETES GENE THERAPY PROGRAM WITH LICENSE OF ADDITIONAL TECHNOLOGY FROM UNIVERSITY OF PITTSBURGH

Genprex, Inc. | December 16, 2022

Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us